David. G
Non-executive Director)
sigmoid pharma
Ireland
Biography
Dr. Goodman is Chief Executive Officer of Pharmascience Inc., a Canadian fully-integrated pharmaceutical company involved in the development, manufacture and distribution of a broad line of generic and branded products. Under Dr. Goodman’s leadership, Pharmascience has grown to become a top ten Canadian Pharmaceutical company, the third largest pharmaceutical company in Canada by number of prescriptions with a diversified portfolio of over 340 product families and sales in more than 60 countries. David obtained his Bachelor of Commerce degree from McGill and a Ph.D. in pharmacology from the University of Virginia. He began his career at Pharmascience in Business Development and prior to being appointed CEO he was Executive Vice President, Pharmascience International.
Research Interest
SmPill® is the main focus of Sigmoid’s current development work and underpins all product development programmes. CyCol®, Sigmoid’s lead clinical development program, which is advancing into Phase 3 trials for moderate to severe ulcerative colitis, was uniquely enabled using SmPill® drug delivery technology.
